Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys

Journal of Infectious Diseases

Volumn 174, Issue 5, 1996, Pages 977-985

  Andersson, Sören ^a   Mäkitalo, Barbro ^b   Thorstensson, Rigmor ^b   Franchini, Genoveffa ^b   Tartaglia, James ^b   Limbach, Keith ^b   Paoletti, Enzo ^b   Putkonen, Per ^b   Biberfeld, Gunnel ^b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOREACTIVITY; MONKEY; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0029999549     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.5.977     Document Type: Article

References (16)

1. Schultz AM, Hu SL. Primate models for HIV vaccines. AIDS 1993;7(suppl 1):S161-70.
2. Schultz AM, Stott EJ. Primate models for AIDS vaccines. AIDS 1994;8(suppl 1):S203-12.
3. McMichael AJ, Gotch FM, Nobel GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309:13-7.
4. Plata F, Cerottini JC, Brunner KT. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system. Eur J Immunol 1975;5:227-33.
5. Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD. Functional activity in vivo of effector T-cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone. Eur J Immunol 1987;17:173-8.
6. Voss G, Hunsmann G. Review: cellular immune response to SIVmac and HIV-2 in macaques: model for the human HIV-1 infection. J Acquir Immune Defic Syndr 1993;6:969-76.
7. Schooley RT. HIV-I - specific cytotoxic T-cell responses. AIDS 1995; 9(suppl A):S113-6.
8. Wahren B. New observations on functional and neutralizing humoral immune response to HIV. AIDS 1994; 8(suppl):S147-53.
9. Putkonen P, Thorstensson R, Walther L, et al. Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses 1991;7:271-7.
10. Putkonen P, Nilsson C, Walther L, et al. Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys. J Med Primatol 1994;23:89-94.
11. Nilsson C, Thorstensson R, Gilljam G, et al. Protection against monkey-cell grown cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp125. Vaccine Res 1995;4:165-75.
12. sm infection by passive immunization in cynomolgus monkeys. Nature 1991;352:436-8.
13. Putkonen P, Thorstensson R, Albert J, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990;4:783-9.
14. Putkonen P, Walther L, Zhang YJ, et al. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med 1995;1:914-8.
15. Girard M, Kieny MP, Pinter A, et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-6.
16. Fultz P, Nara P, Barre-Sinoussi F, et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992;256:1687-90.